ASTRO Supports Prior Authorization Reform in Medicare Advantage to Improve Cancer Care
ASTRO backs bipartisan legislation to reform Medicare Advantage prior authorization, aiming to reduce cancer treatment delays and improve care outcomes.
ASTRO backs bipartisan legislation to reform Medicare Advantage prior authorization, aiming to reduce cancer treatment delays and improve care outcomes.
New Medicare Part D rules in 2025 cap oral cancer drug costs at $2,000 annually and introduce a voluntary monthly payment plan to improve affordability for patients.
New Harvard study compares radiotherapy utilization and spending between Medicare Advantage and Traditional Medicare, highlighting longer treatment durations and higher costs for MA patients.
Recent study links Medicaid expansion under the Affordable Care Act to enhanced lung cancer treatment, with quicker surgeries at high-volume hospitals and better patient outcomes.